Penumbra (PEN) Equity Income (2017 - 2018)
Penumbra (PEN) reported Equity Income of -$920000.0 for Q3 2018, down 68.81% year-over-year from -$2.9 million in Q3 2017, and up 25.2% quarter-over-quarter from -$1.2 million in Q2 2018.
Penumbra (PEN) Equity Income (2017 - 2018) Analysis & Trends
Penumbra (PEN) has 2 years of Equity Income data on file, last reported at -$920000.0 in Q3 2018.
- Equity Income for Q3 2018 came in at -$920000.0, down 68.81% year-over-year; the trailing twelve-month figure through Jun 2019 was -$920000.0 (up 73.36% YoY), and the FY2018 annual result was -$3.1 million, down 116.85% from the prior year.
- Equity Income improved to -$920000.0 in Q3 2018 per PEN's latest filing, from -$1.2 million in the prior quarter.
- Over five years, Equity Income peaked at -$158000.0 in Q2 2017 and troughed at -$1.2 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.68 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Penumbra | 12.45 Bn | 11.84 Bn | 253.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -920,000.00 |
| Jun 30, 2018 | -1.23 Mn |
| Mar 31, 2018 | -951,000.00 |
| Dec 31, 2017 | -727,000.00 |
| Sep 30, 2017 | -545,000.00 |
| Jun 30, 2017 | -158,000.00 |